CGI-58 is a crucial regulator of intracellular energy homeostasis and lipid metabolism via ATGL activation and potential LPAAT activity.
No takes yet. Share an insight, caveat, or question.
Does not alter clinical lipid management; leaves open CGI-58 as a therapeutic target in human metabolic disease.
Zierler et al. (2014) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: